Why The Adaura Study Is A Big Step Forward For Nsclc

Why the ADAURA study is a big step forward for NSCLC

Reflections on the ADAURA study

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

Discussion on the ADAURA study

Xiuning Le, MD, PhD, describes the ADAURA clinical study as an adjuvant treatment in NSCLC

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum

GRACE - Global Resource for Advancing Cancer Education

GRACEcast 2020- Treatment Option Explored in the ADAURA Trial with Dr. Jared Weiss

GRACE - Global Resource for Advancing Cancer Education

Ground-Breaking Data: Phase 3 ADAURA Trial

Targeted Oncology

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

Adjuvant EGFR-Targeted Therapy as a Game Changer in Multimodal NSCLC Management

PeerView Oncology

ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study

European Society for Medical Oncology (ESMO)

The ADAURA Trial: Flaws and Results - Leading Developments & Current Questions in Lung Cancer

GRACE - Global Resource for Advancing Cancer Education

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung Cancer

GRACE - Global Resource for Advancing Cancer Education

ADAURA: osimertinib adjuvant therapy on CNS disease recurrence

ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC

The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023

GRACE - Global Resource for Advancing Cancer Education

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

Should ADAURA Trial Results Change Practice in NSCLC?